Compare SYNA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYNA | ABCL |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2001 | 2020 |
| Metric | SYNA | ABCL |
|---|---|---|
| Price | $97.74 | $11.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $100.78 | $8.40 |
| AVG Volume (30 Days) | 599.1K | ★ 8.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $663,588,000.00 | $75,128,000.00 |
| Revenue This Year | $12.63 | N/A |
| Revenue Next Year | $9.67 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 21.04 | ★ 160.56 |
| 52 Week Low | $58.28 | $2.75 |
| 52 Week High | $149.11 | $12.15 |
| Indicator | SYNA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 77.52 |
| Support Level | $71.55 | $3.38 |
| Resistance Level | $147.97 | N/A |
| Average True Range (ATR) | 4.04 | 0.84 |
| MACD | -0.24 | 0.38 |
| Stochastic Oscillator | 4.11 | 92.57 |
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.